RegenxBio raised $90.04 million in its recent public offering to further its gene therapy development efforts and strengthen its position in the biopharma sector.
PUBLIC · RGNXAug 19, 2026•about 5 hours ago
Amount Raised
$90 Million
Round Type
Post-IPO Equity
RockvilleBiotechnologyHealth Care
Description
RegenxBio, Inc. raised $90.04 million in its second public offering on the Nasdaq Stock Exchange. The biotechnology company specializes in developing gene therapy treatments. Located in Rockville, RegenxBio is recognized for its work in therapies targeting retinal, neuromuscular, and neurodegenerative diseases
Company Information
Company
REGENXBIO
Location
Rockville, Maryland, United States
About
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
Don't miss REGENXBIO's next move
Get an email the moment REGENXBIO raises, hires an exec, or expands, usually minutes after it happens.
RockvilleBiotechnologyHealth Care